The two deals are built differently, and that matters for how option prices can react.
SELLAS Goes to Market the Same Day Its Stock Nearly Tripled
SELLAS announced that it had commenced an underwritten public offering of $150.0 million of common stock, with a 30-day option for the underwriters to buy up to $22.5 million more. J.P. Morgan and TD Cowen are the joint book-running managers. Seeking Alpha timestamped the news at 4:07 p.m. Eastern.
The preliminary prospectus supplement leaves the price per share and the share count blank. It lists clinical development, potential commercialization, working capital and general corporate purposes as uses of the money. It also mentions up to $150 million of stock that remains available under a separate sales agreement with TD Securities.
The timing makes sense in light of the morning. SELLAS said its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia met its overall-survival endpoint (we covered the readout here). According to Cboe's delayed data, SLS opened near $24.09, reached $24.89, and closed at $19.15. That's up about 156% from Monday's $7.47 close. In extended trading it was about $16.90, roughly 12% below the close. Investing.com reported a 10% after-hours drop shortly after the announcement.
AAOI's Fourth ATM of 2026, Sized at $550 Million
Applied Optoelectronics disclosed in an 8-K that it signed an equity distribution agreement with Raymond James and Needham on November 17. The agreement lets it sell up to $550 million of common stock "from time to time." According to the filing:
Stocktwits, via Yahoo Finance, called this the company's fourth ATM program of 2026. It reported that AAOI finished a $600 million program in early October, selling about 5.7 million shares for roughly $588 million net. By our arithmetic, that's an average of a little over $100 a share before costs. Selling the full $550 million at Tuesday evening's price would take about 13 million shares, more than double the October count. The company isn't obligated to sell that much, or anything at all.
AAOI had a busy day before the filing. A Reuters report on a planned U.S. ban on Chinese optical transceivers lifted it at the open, but the gain faded. Cboe data show an open of $48.17 and a close of $45.22, almost flat against Monday's $45.16. After the filing, it traded near $41.60 in extended hours, down about 8%. For context on demand, see our coverage of AAOI's record third quarter.
Why a Fixed-Price Deal and a Drip-Feed Hit the Chain Differently
The two structures create different kinds of uncertainty:
Neither structure changes the terms of listed options. OCC contract adjustments generally cover events like stock splits and certain special dividends, not routine share sales. A Friday $20 SLS call is still a call on 100 shares at $20, however many new shares SELLAS sells.
The two volatility pictures were also very different at the close. SLS 30-day IV was about 147.6, down roughly 385 points on the day. That's the binary trial premium leaving the chain now that the readout is out. AAOI's IV30 was about 122.6, up about 7.6 points, after the transceiver headlines and before the ATM filing.
Where the Evening Prices Sit Against Friday's Straddles
At-the-money straddle midpoints, from Cboe quotes at Tuesday's 4 p.m. close (before either filing), for the November 20 expiration:
| | SLS | AAOI |
This is arithmetic, not a forecast. At those evening prices, both stocks had moved toward their lower break-evens, but neither had reached them. A long straddle bought at the close would still be under water at expiration if the stocks stayed there. A short straddle would still be inside its break-evens, with three sessions left to run.
On the flow: during the regular session, SLS options traded about 301,000 calls and 97,000 puts. The heaviest line was the January 15, 2027 $5 call (about 62,700 contracts), which is deep in the money. AAOI traded about 20,200 calls and 11,400 puts, all before the filing. Its busiest line was a long-dated January 2028 $190 call, with about 1,780 contracts against about 160 open. Volume doesn't show whether those contracts were bought or sold.
The Pricing Print, the Overhang, and Other Things That Can Bite
Defined-risk spreads cap the maximum loss. Uncovered short options do not, and a stock with fresh supply hitting the market can gap.
For background, see our implied volatility explainer and the OCC options disclosure document.
Sources
*By the OptionsPilot Editorial Team. Published November 17, 2026, 4:25 PM PT. Extended-hours prices are 15-minute-delayed Cboe data from early Tuesday evening, and option figures are from Tuesday's 4 p.m. Eastern close; both will change. This article is for education only and is not investment advice. Options involve risk and are not suitable for all investors.*